Liquid Biopsy in <i>EGFR</i>-Mutated Advanced NSCLC from T790M to <i>MET</i> Amplification: Clinical Implications and Possibilities in the Resistance Setting
According to the ESMO and ASCO clinical guidelines, the main role of liquid biopsy in <i>EGFR</i>+ advanced NSCLC patients is represented by T790M detection after erlotinib/gefitinib/afatinib progression. However, the general international expert consensus regards osimertinib as the preferred upfron...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
MDPI AG
2023-04-01
|
| سلاسل: | Journal of Molecular Pathology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.mdpi.com/2673-5261/4/2/9 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
